Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective single-center real-world study of ranibizumab biosimilars for diabetic macular edema
ChiCTR2600127487Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: 3-month mean change in BCVA from baseline and Adverse events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2600127487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127487.